Kornimate/medical-research-clean huggingface dataset:
additional effect of forward head posture correction on temporomandibular dysfunction

Conditions: Temporomandibular Disorder; Forward Head Posture

Summary: the goal of this clinical trial is to test the additional correction effect of nerd neck on damaged jaw in people who suffers from jaw problems and nerd neck at the same time. the main question it aims to answer: • whether the additional correction of nerd neck impact the jaw features of pain and function. participants will: * participants will be given the consent to sign first. * participants will be assessed to check jaw pain and function. * participants will be divided randomly into 2 groups. * each group will be given the treatment sessions for 6 weeks. * participants will come back after 6 weeks for another last assessment. researchers will compare regular treatment for jaw with new device, regular only and dental treatment groups to see if there is improvement in jaw characteristics.

the relationship between the two conditions of forward head posture (fhp) and temporomandibular joint dysfunction (tmd) have been previously stated with comparing the craniocervical angle (cva) of tmd patients to the healthy individuals, still a clear relationship couldn't be drawn due to different study limitations such as the lack of subdivision in the tmd patients based on their diagnostic subcategories in addition to, patients' posture might have been altered while the photo was captured. ever since, multiple researchers deliberately investigated the two conditions association and inferred the following: 1. fhp can be a risk factor resulting in tmd where any alteration in the head position produces more tension on the masticatory muscles by changing the mandible position 2. tmd origins from muscular component is more significant than articular component yet the correlation between head posture and tmd is still not clear enough, however, if fhp and myogenic tmd were linked preventive measures can be taken. recently, multiple studies established a relation between the occurrence of fhp in tmd patients which supported the suspected relation between them but without a clear association. till present, no study has investigated the additional effect of fhp dcto correction impact on myogenic tmd, and this is where the purpose of this study arises from.

Eligibility criteria:
inclusion criteria: * the participant experiencing one or more of tmd signs or symptoms and has been diagnosed with tmd beside having forward head posture with craniocervical (cva) angle \< 50. * the study will be limited to the patients in the dental clinic of the university of sharjah. * participants experiencing mild to moderate myogenic tmd with symptoms of orofacial pain and limited range of jaw opening. exclusion criteria: * previous head, neck or tmj traumas. * history of temporomandibular joint surgery.

Keywords: temporomandibular dysfunction pain traction conservative treatment
phase ii trial to correlate radiographic response induced by gefitinib with mutations in the protein-tyrosine kinase domain of the egf receptor gene

Conditions: Lung Cancer; Non-small Cell Lung Cancer; Bronchioloalveolar Cancer

Summary: the purpose of this research study is to: * see if gefitinib pills can shrink stage 1 or 2 non-small cell lung cancers before surgery * see if your non-small cell lung cancer has a mutation in a certain part of the egfr gene * see if patients whose tumor does shrink with gefitinib treatment are more likely to have a mutation in a certain part of the egfr gene * see if the pattern of protein expression in the blood is related to the tumor's sensitivity or resistance to gefitinib treatment. * see if expression of certain genes in the tumor are related to the tumor's sensitivity or resistance to gefitinib treatment.

this is a phase ii, single institution trial to correlate gefitinib response and mutations in the protein-tyrosine kinase domain of the egf receptor gene. the study will be conducted in patients with stage i and ii nsclc who have been determined to be operable and resectable. patients must have 1 or more of the following features: never smoker or smoking history of \< 15 pack years and/or features of bronchioloalveolar lung cancer. 50 patients will be enrolled on this study. treatment will be with gefitinib for at least 21 days before surgery (depending on the timing of the surgery). patients will discontinue gefitinib 2 days before their operation. for patients that demonstrate a radiographic response to gefitinib preoperatively and /or patients with mutations in the protein-tyrosine kinase domain of the egf receptor gene (identified from the surgical sample), gefitinib will continue for 2 years post-surgery. patients who do not have evidence of radiographic response or mutations in the protein-tyrosine kinase domain of the egf receptor gene will be removed from the study.

Eligibility criteria:
inclusion criteria: * pathologic confirmation of malignancy at memorial sloan-kettering * patients must have previously untreated stage i or ii nsclc (t11-2n0m0, t1-2n1m0, t3n0m0) and 1 of the following features: never smoker or \< 15 pack year smoking history and/or bronchioloalveolar cancer (either pure bac, bac with focal invasion or adenocarcinoma with bac features) * patients must have been determined to be operable and resectable by the treating thoracic surgeon. * age \>18 years. * measurable indicator lesions * ability to understand and the willingness to sign a written informed consent document. exclusion criteria: * pregnant or lactating women or women of childbearing potential not using effective contraception. men participating in the trial must also use effective contraception when sexually active. * patients may not be receiving any other investigational agents. * any history of or evidence of interstitial lung disease (patients with chronic stable radiographic changes who are asymptomatic need not be excluded).

Keywords: lung cancer non-small cell lung cancer gefitnib cancer nsclc bronchioloalveolar cancer smoker
studying tumor samples from women who have undergone chemotherapy for breast cancer

Conditions: Breast Cancer

Summary: rationale: studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in dna and identify biomarkers related to cancer. purpose: this research study is looking at tumor samples from women who have undergone chemotherapy for breast cancer.

objectives: primary * to identify gene sets for risk of recurrence using molecular profiling in samples from women with lymph node-positive or high-risk lymph node-negative breast cancer on clinical trial ecog-e2197. secondary * to define a set of significant genes as prognostic markers of recurrence. * to compare the prognostic value of the oncotype dx™ (odx) 21 gene assay of clinical trial with gene sets determined in this study. * to compare the dasl™ assay of the odx 21 genes with odx assay results of clinical trial. * to compare the prognostic value of selected genes with gene sets determined in this study. outline: this is a multicenter study. samples are used in molecular profiling by applying a custom panel of breast cancer-related genes to a cdna-mediated annealing, selection, extension, and ligation (dasl™) assay, immunohistochemistry, and other studies.

Eligibility criteria:
disease characteristics: * histologically confirmed breast cancer tumor samples collected on clinical trial ecog-e2197 * histologically lymph node-positive (n1-3) or high-risk lymph node-negative disease * hormone receptor-positive or negative disease (status known) * her2 status known patient characteristics: * menopausal status not specified prior concurrent therapy: * see disease characteristics

Keywords: stage ii breast cancer stage iiia breast cancer stage iiib breast cancer
chronic pelvic pain syndrome in males

Conditions: Pelvic Pain Syndrome

Summary: the aim of this study is to evaluate the effectiveness of eswt (extracorporeal shock wave therapy) and tens (transcutaneous electrical nerve stimulation) in individuals diagnosed with chronic pelvic pain syndrome and treated with medication. the study was organized as a randomized controlled trial. the sample size is 30 patients suffering from chronic pelvic pain syndrome.

volunteers who are between the ages of 20-40, diagnosed with chronic pelvic pain syndrome, and who meet the inclusion criteria will be included in the study and will be randomized into 2 groups: group i (tens) and group ii (eswt).

Eligibility criteria:
inclusion criteria: 1. aged between 20-40 years old males 2. diagnosis of chronic pelvic pain syndrome exclusion criteria: 1. cancer 2. surgery related to pelvic floor 2. receiving drug treatment

Keywords: chronic pelvic pain syndrome male eswt tens
ultrasound measurement of quadriceps shortening during neuromuscular electrical stimulation in critically ill patients

Conditions: ICU Acquired Weakness; Quadriceps Muscle Atrophy

Summary: icu-aw is highly prevalent (50%) among critically ill patients. its diagnosis is usually delayed as it requires patients' awakening and collaboration to provide accurate measurement. this study aims to investigate the accuracy of an early ultrasound measurement of quadriceps shortening during neuromuscular electrical stimulation to diagnose future icu-aw in critically ill patients.


Eligibility criteria:
inclusion criteria: * mechanical ventilation for at least 24 hours exclusion criteria: * decision to withhold life-sustaining treatment * pregnancy * degenerative neurological pathology with disabling muscle weakness * pace maker * inability to communicate * chronic loss of autonomy described by the patient's family * guardianship
treatment protocol for clofazamine in the long term treatment of leprosy

Conditions: Leprosy

Summary: clofazimine has shown effectiveness in the treatment of leprosy for many years. the world health organization and the national hansen's disease program consider clofazamine to be standard therapy for treatment of multibacillary leprosy. in recent years, the availability of the drug has become limited and is currently available only under a research protocol and is considered "investigational." use of clofazamine in patients presenting with lepromatous leprosy is necessary for patients exhibiting nerve involvement or lesions resistant to other therapies. this drug will be used prospectively for patients who require treatment of leprosy as deemed appropriate by a kaiser permanente southern california physician.

treatment protocol objective is to treat patients with clofazamine who meet inclusion criteria stated above.

Eligibility criteria:
inclusion criteria: * known or suspected leprosy confirmed by skin biopsy and/or slit skin smears. * multibacillary leprosy (lepromatous leprosy or borderline-lepromatous). * paucibacillary leprosy (borderline, borderline tuberculoid, or indeterminate) if there is involvement of the cranial nerves or active acute neuritis. * known or suspected enl(erythema nodosum leprosum) (a specific immune reaction with painful skin nodules and fever) * known or suspected dapsone-resistant leprosy or relapsed leprosy. * intolerance of other antileprosy antibiotic (where clofazamine is substituted as apart of multidrug regimen) exclusion criteria: * uncomplicated paucibacillary leprosy which would otherwise be treated with dapsone and rifampin only. * known prior intolerance of clofazamine * any minor (even with parental consent) * any fertile woman who is pregnant a specific immune reaction with painful skin rash and fever)

Keywords: multibacillary leprosy leprosy clofazamine
a medical research study to evaluate the effects of act-246475 in adults with heart attack

Conditions: Acute Myocardial Infarction

Summary: the goal of this study is to find out how fast a drug called selatogrel (act-246475) can prevent platelets from binding together. this study will also help to find out more about the safety of this new drug. the drug selatogrel (act-246475) will be used in 2 different doses (8 mg or 16 mg) and will be administered in the thigh.

this study is planned in patients presenting with acute myocardial infarction (ami) scheduled for an invasive strategy. platelet activation and thrombus formation play a pivotal role in the pathophysiology of acute coronary syndrome. early platelet inhibition has been shown to reduce the risk of recurrent events after a myocardial infarction. the screening period starts when the participant provides informed consent and ends with participant's randomization. eligible participants had an acute myocardial infarction (ami; st-segment elevation myocardial infarction \[stemi\] or non-st-elevation myocardial infarction \[nstemi\]), a life-threatening condition, and will therefore fulfill the ich-gcp definition of vulnerable subjects ("persons in emergency situations"). accordingly, a specific process for obtaining consent in compliance with local regulations and approved by the independent ethics committee will be implemented. the study will be performed during a participant's hospital stay related to the qualifying ami. standard treatment of ami is allowed including anticoagulants. ticagrelor will be the only oral p2y12 receptor antagonist allowed to be initiated during the study and its administration will be possible only after selatogrel administration. use of fibrinolytics or gpiib/iiia inhibitors will be prohibited unless required for bail-out. all other standard-of-care treatments for ami will be allowed without restriction. the treatment period starts with the participant's randomization and ends after the end-of-study assessments, approximately 48 hours after the administration of a single study treatment dose.

Eligibility criteria:
main inclusion criteria: * informed consent obtained prior to any study-mandated procedure, * males aged from 18 to 85 and postmenopausal females aged up to 85 years, * onset of symptoms of ami of more than 30 min and less than 6 hours prior to randomization, * subjects presenting a type i ami including stemi or nstemi. main exclusion criteria: * cardiogenic shock or severe hemodynamic instability, * cardiopulmonary resuscitation, * loading dose of any oral p2y12 receptor antagonist prior to randomization, * planned fibrinolytic therapy or any fibrinolytic therapy administered within 24 h prior to randomization, * known platelet disorders (e.g., thromboasthenia, thrombocytopenia, von willebrand disease). * active internal bleeding, or bleeding diathesis or conditions associated with high risk of bleeding. * known clinically important anemia. * oral anticoagulation therapy within 7 days prior to randomization
patient-centric chronic pancreatitis registry (pact-cp)

Conditions: Chronic Pancreatitis

Summary: the main objective of this study is to generate real-world evidence reflecting the experience of individuals with exocrine pancreatic insufficiency (epi) due to chronic pancreatitis (cp). efforts will be directed toward understanding the unmet need and therapeutic burden to identify the most critical factors that influence treatment choices/prescribing patterns, quality of life, and healthcare utilization outcomes in standard of care for individuals with epi due to cp.

study participants will be followed prospectively, and data from study participants will be collected at 3-month intervals via electronic data capture (edc) portal. investigators will complete assessments approximately every 6 months at the time of routine clinical encounters. adverse events (aes) will be collected as part of the study data collection forms. serious adverse events (saes) are to be reported within 24 hours (1 business day) of awareness, whether or not the site learns of the event at the time of a registry follow-up visit.

Eligibility criteria:
inclusion criteria: to be eligible for enrollment, a study participant must meet the inclusion criteria below: 1. at least 18 years of age (or age of majority) 2. willing to provide consent to participate 3. meet one (1) of the following at the time of enrollment: 1. diagnosis of chronic pancreatitis (cp) 2. diagnosis of recurrent acute pancreatitis (rap) 4. suspected or confirmed diagnosis of epi made by a healthcare provider 5. on pancreatic enzyme replacement therapy (pert), either prior to the enrollment visit or newly prescribed at the time of the enrollment visit. to be eligible for enrollment into the registry, a study participant must not have any of the criteria below: 1. currently participating in or planning to participate in a double-blind randomized trial and/or open-label phase 3b/4 on cp or epi 2. diagnosed with any of the following conditions at the time of enrollment: 1. cystic fibrosis 2. fibrosing colonopathy 3. a history of or current diagnosis of pancreatic cancer, main duct papillary mucinous neoplasms (ipmns), and other pancreatic malignancies 4. allergy to pork or other porcine pancreatic enzyme products (peps) 5. any condition that would, in the investigator's opinion, limit the individual's ability to complete the study. - exclusion criteria: -
safety and efficacy study of cls001topical gel compared to vehicle in subjects with inflammatory acne vulgaris

Conditions: Acne Vulgaris

Summary: the primary objective of this study is to evaluate the safety and efficacy of once-daily topical application of cls001 1%, 1.75% and 2.5% topical gel compared to vehicle topical gel in subjects with inflammatory acne vulgaris


Eligibility criteria:
inclusion criteria: * male or non-pregnant female subjects with facial acne vulgaris, 12 years of age or older. * subjects with ≥20 inflammatory facial lesions (papules, pustules) inclusive of the nose, with a maximum of 9 inflammatory pustules. * an investigator's global assessment (iga) of moderate (3) or severe (4) exclusion criteria: * subjects with acne conglobate, acne fulminans, and secondary acne (chloracne, drug-induced acne, polycystic ovarian syndrome, etc.) * subjects with greater that 75 facial non-inflammatory lesions (open and/or closed comedones; excluding the nose) * subjects with more than 2 facial nodulocystic lesions
whole body vibration effect on trunk control, functional performance and selective control

Conditions: Cerebral Palsy

Summary: permanent neurological disorders such as cerebral palsy lead to problems with motor, sensory, and cognitive functions, which in turn limit one's ability to do certain activities. while the exact causes of cerebral palsy differ from child to child, anoxia-induced brain injury is a major cause of the disorder. the body parts affected, tone, and involuntary motions are used to categorise cerebral palsy. among all the forms, spastic cp is the most prevalent. in individuals with cp, postural stabilisation and adaptations of the head, trunk, pelvic, and shoulder girdles grow more slowly. the primary problem with cp children is their gross movement pattern, which prevents them from performing single joint movements. muscle strength increases significantly with wbv exercise training, which also reduces spasticity and enhances cp children's motor function. this study is important because it will determine whether wbv improves trunk control, functional performance, and lower limb selective control. data from rising sun institute will be gathered for this randomised clinical trial. 38 patients will be included in the study. the study's inclusion criteria will include cp children with ages between 6 and 12 years old, those who can stand or walk alone (even with unusual gait patterns), gmfcs i and ii, and children with diplegic cerebral palsy. children with cerebral palsy (cp) who have had a lower limb fracture, fixed contracture, or other deformity, as well as those who have had a botulinum toxin injection or selective dorsal rhizotomy within the last six months, will not be eligible. stretching exercises, strengthening exercises, trunk control facilitation, and rightening reaction facilitation will be the specific physical therapy treatments administered to group a. in addition, group b will receive wbv in addition to the specific physical therapy treatments (stretching exercises, strengthening exercises, trunk control facilitation, and rightening reaction facilitation). for two months, the 30-minute sessions will be held three times a week. the modified trost test will test selective lower limb control, the pedi scale will assess functional performance, and the trunk control measurement scale will monitor trunk stability before and after sessions. spss version 26 will be utilised for data analysis.


Eligibility criteria:
inclusion criteria: * • childrens who follow verbal command * childrens who can stand or walk alone (either with altered pattern) * age limit: 6 -12 years * gmfcs i \& ii * diplegic cerebral palsy exclusion criteria: * • childrens with history of fracture in last 6 months * childrens with fixed contracture or other deformity of lower limb * childrens having visual or auditory impairments * selective dorsal rhizotomy or botulinum toxin injection to lower extremities within past six months

Keywords: whole body vibration cerebral palsy trunk control muscle performance selective motor control
silent sinus syndrome (first case report, saudi arabia with recommendation)

Conditions: SILENT SINUS SYNDROME

Summary: silent sinus syndrome is a rare disorder that presents a diagnostic challenge, most of the patients with this syndrome present with ophthalmological complaints without any nasal sinus symptoms, and it has a painless course and slow development. a case report of a 37-years-old-female who was complaining of severe throbbing pain since 2009, is presented here where the diagnosis of sss was obtained in 2018, this delay in diagnosing the situation had affected the patient lifestyle tremendously.

silent sinus syndrome is a rare disorder that presents a diagnostic challenge, most of the patients with this syndrome present with ophthalmological complaints without any nasal sinus symptoms, and it has a painless course and slow development. the syndrome can be diagnosed clinically and confirmed radiologically, and ct imaging is considered the gold standard for its diagnosis. the classical radiographic findings are opacification and collapse of the sinus walls. functional endoscopic sinus surgery (fess) is the standard gold treatment of choice to arrest the progression of the disease. a case report of a 37-years-old-female who was complaining of severe throbbing pain since 2009, is presented here where the diagnosis of sss was obtained in 2018, this delay in diagnosing the situation had affected the patient lifestyle tremendously. accordingly, knowledge of the signs and features of sss can result in an accurate diagnosis. suspected cases of silent sinus syndrome require prompt ear, nose, and throat referral for consideration of definitive diagnosis and surgical management. nasal endoscopy and clinical evaluation are also essential for the diagnosis. our recommendation is to consider sss as a differential diagnosis for patients with spontaneous enophthalmos and hypoglobus, even in the absence of maxillary sinus opacification. moreover, encourage all the specialists in the medical and the dental field to communicate well together in cases like this.

Eligibility criteria:
inclusion criteria: signs or symptoms in the eyes. signs in the sinus that seen by x-ray. exclusion criteria: children ( \<7 years old)

Keywords: case report silent sinus syndrome sss ct mri functional endoscopic sinus surgery
follow up and observation of charcot marie tooth disease in families

Conditions: Charcot-Marie-Tooth Disease

Summary: the study is aimed to test the hypothesis that there is anticipation in cmt


Eligibility criteria:
inclusion criteria:patients with genetically confirmed cmt 1a disease - exclusion criteria: -

Keywords: familial peripheral neuropathy anticipation